C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.080
-0.090 (-2.84%)
May 12, 2026, 9:33 AM EDT - Market open
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $6.15M in the quarter ending March 31, 2026, with 18.83% growth. This brings the company's revenue in the last twelve months to $35.64M, up 0.15% year-over-year. In the year 2025, C4 Therapeutics had annual revenue of $35.95M with 1.02% growth.
Revenue (ttm)
$35.64M
Revenue Growth
+0.15%
P/S Ratio
9.72
Revenue / Employee
$345,644
Employees
104
Market Cap
339.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 35.95M | 363.00K | 1.02% |
| Dec 31, 2024 | 35.58M | 4.49M | 14.43% |
| Dec 31, 2022 | 31.10M | -14.69M | -32.08% |
| Dec 31, 2021 | 45.79M | 12.59M | 37.93% |
| Dec 31, 2020 | 33.20M | 11.81M | 55.25% |
| Dec 31, 2019 | 21.38M | 2.02M | 10.42% |
| Dec 31, 2018 | 19.36M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 227.18M |
| Opus Genetics | 14.20M |
| Surrozen | 7.49M |
| Abeona Therapeutics | 5.82M |
| Compass Therapeutics | 850.00K |
| Silence Therapeutics | 839.00K |
| Inhibikase Therapeutics | 1.00 |
CCCC News
- 54 minutes ago - C4 Therapeutics reports Q1 EPS (20c), consensus (26c) - TheFly
- 2 hours ago - C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion - Reuters
- 4 weeks ago - C4 Therapeutics expands long-term partnership with Roche - TheFly
- 4 weeks ago - C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs) - GlobeNewsWire
- 6 weeks ago - C4 Therapeutics doses first patient in cemsidomide trial - TheFly
- 6 weeks ago - C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 2 months ago - C4 Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts